alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7192 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
118th CONGRESS
  2d Session
                                H. R. 7192

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
 at 333 West Broadway in Anaheim, California, as the ``Dr. William I. 
                  `Bill' Kott Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DR. WILLIAM I. ``BILL'' KOTT POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 333 West Broadway in Anaheim, California, shall be known and 
designated as the ``Dr. William I. `Bill' Kott Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Dr. 
William I. `Bill' Kott Post Office Building''.

            Passed the House of Representatives June 3, 2024.

            Attest:

                                                                 Clerk.
118th CONGRESS

  2d Session

                               H. R. 7192

_______________________________________________________________________

                                 AN ACT

 To designate the facility of the United States Postal Service located 
 at 333 West Broadway in Anaheim, California, as the ``Dr. William I. 
                  `Bill' Kott Post Office Building''.
```
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 95-7879

RANDY LEE HEIM,

Petitioner - Appellant,

versus

RONALD J. ANGELONE, Director of the Virginia

Department of Corrections,

Respondent - Appellee.

Appeal from the United States District Court for the Eastern District of Virginia, at Norfolk. Henry C. Morgan, Jr., District

Judge. (CA-94-1054-2)

Submitted: May 28, 1996 Decided: June 4, 1996

Before NIEMEYER, WILLIAMS, and MOTZ, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Randy Lee Heim, Appellant Pro Se. Katherine P. Baldwin, OFFICE OF

THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Appellant seeks to appeal the district court's order denying

relief on his 28 U.S.C. § 2254 (1988) petition. We have reviewed

the record and the district court's opinion accepting the recommendation of the magistrate judge and find no reversible error.

Accordingly, we deny a certificate of appealability and dismiss the

appeal on the reasoning of the district court. Heim v. Angelone,

No. CA-94-1054-2 (E.D. Va. Oct. 19, 1995). We dispense with oral

argument because the facts and legal contentions are adequately

presented in the materials before the court and argument would not

aid the decisional process.

DISMISSED
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. FDA-2010-N-0374]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

The Food and Drug Administration (FDA) is announcing that a collection of information entitled “Petition to Request an Exemption From 100 Percent Identity Testing of Dietary Ingredients; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

# FOR FURTHER INFORMATION CONTACT:

Denver Presley, Jr., Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-3793.

# SUPPLEMENTARY INFORMATION:

                    In the                     **Federal Register**                     of September 30, 2010 (75 FR 60463), the Agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0608. The approval expires on December 31, 2013. A copy of the supporting statement for this information collection is available on the Internet at                     *http://www.reginfo.gov/​public/​do/​PRAMain*.                

Dated: December 27, 2010.

David Dorsey,

Acting Deputy Commissioner for Policy, Planning and Budget.

[FR Doc. 2010-33209 Filed 1-3-11; 8:45 am]

BILLING CODE 4160-01-P
##### 



EXHIBIT 31.2
CERTIFICATION PURSUANT TO
EXCHANGE ACT RULE 13a-14(a) I, David Thompson, certify that:  1.

I have reviewed this Report on Form 10-Q of International Absorbents Inc.;2.

Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;3.

Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;4.

The registrants other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the registrant and have:  (a)

Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in
which this report is being prepared;(b)

Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and(c)

Disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter
(the registrants fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrants
internal control over financial reporting; and  5.

The registrants other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the
audit committee of the registrants board of directors (or persons performing the equivalent
functions):  (a)

All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrants ability to record, process, summarize and report financial
information; and(b)

Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal control over financial
reporting. Date: June 10, 2005
    
    /s/ David H. Thompson
David H. ThompsonSecretary and Chief Financial Officer
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7202 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7202

  To direct the Secretary of State to submit to Congress a report on 
funding provided by the United States to the United Nations Relief and 
Works Agency for Palestinian Refugees in the Near East (UNRWA), and for 
                            other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 1, 2024

 Mr. Jackson of Texas (for himself, Ms. Stefanik, Mr. Babin, Mr. Bost, 
Ms. Van Duyne, Mr. Fallon, Mr. Nehls, Mrs. Miller of West Virginia, Mr. 
Pfluger, Mr. Norman, Ms. Boebert, Mr. Bergman, Mr. Perry, Mr. Self, Mr. 
 Bilirakis, Mr. Van Drew, Mr. Lawler, and Ms. Hageman) introduced the 
 following bill; which was referred to the Committee on Foreign Affairs

_______________________________________________________________________

                                 A BILL

 
  To direct the Secretary of State to submit to Congress a report on 
funding provided by the United States to the United Nations Relief and 
Works Agency for Palestinian Refugees in the Near East (UNRWA), and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Uncovering UNRWA's Terrorist Crimes 
Act''.

SEC. 2. REPORT.

    Not later than 90 days after the date of the enactment of this Act, 
the Secretary of State shall submit to Congress a report that--
            (1) identifies the total amounts of funding provided by the 
        United States to the United Nations Relief and Works Agency for 
        Palestinian Refugees in the Near East (UNRWA) during fiscal 
        years 2020 through 2024, including an identification of such 
        amounts disaggregated by calendar month of such fiscal years; 
        and
            (2) a description of how such funds were spent.

SEC. 3. PROHIBITION.

    Effective beginning on the date of the enactment of this Act, no 
Federal funds may be used to provide funding, directly or indirectly, 
to UNRWA.
                                 <all>
```
### TEXA S C OU R T OF A PPEAL S, THIR D DIST R ICT , AT AU STIN
NO. 03-0 9 -00 737 -CV

Ex Par te Walte r Lee Hall, Jr.

F ROM THE DISTRICT CO URT OF TRAVIS COUNTY , 261S T JUDICIAL DISTRICT NO. D-1- GV-09- 0020 35 , HO NORAB LE SUZ ANNE COVINGTO N , JUDGE PRESIDI NG

M E M O R

A N D U M O P I N I O N
Walter L ee Ha l l, J r., filed his notice of appea l on Dece mber 23, 2009. On May 18, 2010, we se nt Hall a notice that his brief wa s overdue . On J une 14, 2010, Ha ll fil ed a motion for extension of time to f ile his br ief. This Court gr anted his motion on J une 23, 2010, and informed Ha ll that his brief was due by J uly 2, 2010. Fur ther, this Court warne d Hall that if he f ailed to f i l e his brief by

that deadline, his a

ppeal would be dismiss ed for want of pr osecution. To date , Ha ll h a s n ot f

ile d a fu rt he r mot ion to exte nd or a br ie f in this c a se . F or that r e a so n, we dis mis s th is appea l for wa

nt of prosec ution. See Tex. R. App. P . 42.3(b).

__________________________________________ David Pury ear , J ustice Be fore Chief J ustice Jones, J ustices Pury ear and Pember

ton Dismissed for Want of Prosecution Filed: August 3, 2010
#### § 1308.22 Excluded substances.

The following nonnarcotic substances which may, under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301), be lawfully sold over the counter without a prescription, are excluded from all schedules pursuant to section 201(g) (1) of the Act (21 U.S.C. 811(g) (1)):

| Company | Trade name | NDC code | Form | Controlled substance | (mg or mg/ml) |
| --- | --- | --- | --- | --- | --- |
| Aphena Pharma Solutions—New York, LLC | Nasal Decongestant Inhaler/Vapor Inhaler | | IN | Levmetamfetamine (l-Desoxyephedrine) | 50.00 |
| Bioline Laboratories | Theophed | 00719-1945 | TB | Phenobarbital | 8.00 |
| Goldline Laboratories | Guiaphed Elixir | 00182-1377 | EL | Phenobarbital | 4.00 |
| Goldline Laboratories | Tedrigen Tablets | 00182-0134 | TB | Phenobarbital | 8.00 |
| Hawthorne Products Inc | Choate's Leg Freeze | | LQ | Chloral hydrate | 246.67 |
| Parke-Davis & Co | Tedral | 00071-0230 | TB | Phenobarbital | 8.00 |
| Parke-Davis & Co | Tedral Elixir | 00071-0242 | EX | Phenobarbital | 40.00 |
| Parke-Davis & Co | Tedral S.A. | 00071-0231 | TB | Phenobarbital | 8.00 |
| Parke-Davis & Co | Tedral Suspension | 00071-0237 | SU | Phenobarbital | 80.00 |
| Parmed Pharmacy | Asma-Ese | 00349-2018 | TB | Phenobarbital | 8.10 |
| Procter & Gamble Co., The | Vicks VapoInhaler | 37000-686-01 | IN | Levmetamfetamine (*l*-Desoxyephedrine) | 50.00 |
| Rondex Labs | Azma-Aids | 00367-3153 | TB | Phenobarbital | 8.00 |
| Smith Kline Consumer | Benzedrex | 49692-0928 | IN | Propylhexedrine | 250.00 |
| Sterling Drug, Inc | Bronkolixir | 00057-1004 | EL | Phenobarbital | 0.80 |
| Sterling Drug, Inc | Bronkotabs | 00057-1005 | TB | Phenobarbital | 8.00 |
| White Hall Labs | Primatene (P-tablets) | 00573-2940 | TB | Phenobarbital | 8.00 |

Excluded Nonnarcotic Products

[38 FR 8255, Mar. 30, 1973. Redesignated at 38 FR 26609, Sept. 24, 1973, and amended at 41 FR 16553, Apr. 20, 1976; 41 FR 53477, Dec. 7, 1976; 46 FR 51603, Oct. 21, 1981; 47 FR 45867, Oct. 14, 1982; 54 FR 2100, Jan. 19, 1989; 55 FR 12162, Mar. 30, 1990; 62 FR 13968, Mar. 24, 1997; 74 FR 44283, Aug. 28, 2009; 80 FR 65634, 65637, Oct. 27, 2015; 81 FR 6453, Feb. 8, 2016]
I 

118TH CONGRESS 

2D SESSION H. R. 7193 

To amend the Clean Air Act to provide for exclusion of air quality monitoring 

data that is directly due to a catastrophic or beneficial use wildfire 

from use in determinations with respect to exceedances or violations 

of the national ambient air quality standard for any air pollutant, and 

for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 1, 2024 

Mr. CURTIS introduced the following bill; which was referred to the Committee 

on Energy and Commerce 

A BILL 

To amend the Clean Air Act to provide for exclusion of 

air quality monitoring data that is directly due to a 

catastrophic or beneficial use wildfire from use in determinations with respect to exceedances or violations of 

the national ambient air quality standard for any air 

pollutant, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Wildfire Air Quality 

5 Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7193 IH

1 SEC. 2. AIR QUALITY MONITORING DATA EXCLUDED DUR2 ING A WILDFIRE EVENT. 

3 (a) IN GENERAL.—Section 319 of the Clean Air Act 

4 (42 U.S.C. 7619) is amended by adding at the end the 

5 following: 

6 ‘‘(c) AIR QUALITY MONITORING DATA EXCLUDED

7 DURING A WILDFIRE EVENT.—In the event of a cata8 strophic or beneficial use wildfire determined by the Ad9 ministrator to have a significant impact on air quality, the 

10 Administrator shall exclude air quality monitoring data 

11 that is directly due to such wildfire from use in determina12 tions by the Administrator with respect to exceedances or 

13 violations of the national ambient air quality standard for 

14 any air pollutant.’’. 

15 (b) RULEMAKING.—Not later than 90 days after the 

16 date of enactment of this Act, the Administrator of the 

17 Environmental Protection Agency shall publish a final rule 

18 to carry out the amendment made by subsection (a). 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
§ 1316.03 Authority to make inspections. In carrying out his functions under the Act, the Administrator, through his inspectors, is authorized in accordance with sections 510 and 1015 of the Act (21 U.S.C. 880 and 965) to enter controlled premises and conduct administrative inspections thereof, for the purpose of: ( a ) Inspecting, copying, and verifying the correctness of records, reports, or other documents required to be kept or made under the Act and regulations promulgated under the Act, including, but not limited to, inventory and other records required to be kept pursuant to part 1304 of this chapter, order form records required to be kept pursuant to part 1305 of this chapter, prescription and distribution records required to be kept pursuant to part 1306 of this chapter, records of listed chemicals, tableting machines, and encapsulating machines required to be kept pursuant to part 1310 of this chapter, import/export records of listed chemicals required to be kept pursuant to part 1313 of this chapter, shipping records identifying the name of each carrier used and the date and quantity of each shipment, and storage records identifying the name of each warehouse used and the date and quantity of each storage.
( b ) Inspecting within reasonable limits and to a reasonable manner all pertinent equipment, finished and unfinished controlled substances, listed chemicals, and other substances or materials, containers, and labeling found at the controlled premises relating to this Act;
( c ) Making a physical inventory of all controlled substances and listed chemicals on-hand at the premises;
( d ) Collecting samples of controlled substances or listed chemicals (in the event any samples are collected during an inspection, the inspector shall issue a receipt for such samples on DEA Form 400 to the owner, operator, or agent in charge of the premises);
( e ) Checking of records and information on distribution of controlled substances or listed chemicals by the registrant or regulated person (*i.e.*, has the distribution of controlled substances or listed chemicals increased markedly within the past year, and if so why);
( f ) Except as provided in § 1316.04, all other things therein (including records, files, papers, processes, controls and facilities) appropriate for verification of the records, reports, documents referred to above or otherwise bearing on the provisions of the Act and the regulations thereunder.
[36 FR 7820, Apr. 24, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973, and amended at 51 FR 5319, Feb. 13, 1986; 55 FR 50827, Dec. 11, 1990; 60 FR 32465, June 22, 1995; 77 FR 4238, Jan. 27, 2012]
§ 16.24 Regulatory hearing required by the act or a regulation. ( a ) A regulatory hearing required by the act or a regulation under § 16.1(b) will be initiated in the same manner as other regulatory hearings subject to the additional procedures in this section.
( b ) [Reserved]
( c ) The notice will state whether any action concerning the matter that is the subject of the opportunity for hearing is or is not being taken pending the hearing under paragraph (d) of this section.
( d ) The Commissioner may take such action pending a hearing under this section as the Commissioner concludes is necessary to protect the public health, except where expressly prohibited by statute or regulation. A hearing to consider action already taken, and not stayed by the Commissioner, will be conducted on an expedited basis.
( e ) The hearing may not be required to be held at a time less than 2 working days after receipt of the request for hearing.
( f ) Before the hearing, FDA will give to the party requesting the hearing reasonable notice of the matters to be considered at the hearing, including a comprehensive statement of the basis for the decision or action taken or proposed that is the subject of the hearing and a general summary of the information that will be presented by FDA at the hearing in support of the decision or action. This information may be given orally or in writing, in the discretion of FDA.
( g ) FDA and the party requesting the hearing will, if feasible, at least 1 day before the hearing provide to each other written notice of any published articles or written information to be presented at or relied on at the hearing. A copy will also be provided in advance if the other participant could not reasonably be expected to have or be able to obtain a copy. If written notice or a copy is not provided, the presiding officer may, if time permits, allow the party who did not receive the notice or copy additional time after the close of the hearing to make a submission concerning the article or information.
[44 FR 22367, Apr. 13, 1979, as amended at 47 FR 26375, June 18, 1982; 54 FR 9037, Mar. 3, 1989]
TS-CKHI01

Attachment #7

Pt. 2, Sec. B, 1a 

Processing Information on the New Chemical Substance at Industrial Sites 

Controlled by Others